Neuroprotective activity of stiripentol with a possible involvement of voltage-dependent calcium and sodium channels

Journal of Neuroscience Research

Volumn 94, Issue 2, 2016, Pages 179-189

  Verleye, Marc ^a   Buttigieg, Dorothée ^b   Steinschneider, Rémy ^b  

^a Service de Pharmacologie   (France)

^b Neuron Experts SAS   (France)

Author keywords

L glutamate; Neuronal astroglial culture; Neuroprotection; Oxygen glucose deprivation; Stiripentol; Voltage gated sodium and calcium channels

Indexed keywords

CALCIUM ION; GLUCOSE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; OXYGEN; SODIUM ION; STIRIPENTOL; VERATRIDINE; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL; 1,3 DIOXOLANE DERIVATIVE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM; DESULFATOHIRUDIN; FIBRINOLYTIC AGENT; HIRUDIN DERIVATIVE; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN H; NEUROPROTECTIVE AGENT; PROTEIN BINDING; RECOMBINANT PROTEIN; SODIUM; TRITIUM;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; CALCIUM TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; EMBRYO; FEMALE; IC50; IN VITRO STUDY; NERVE CELL NETWORK; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; RAT; SODIUM TRANSPORT; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; GLIA; HIPPOCAMPUS; MAMMALIAN EMBRYO; METABOLISM; NERVE CELL;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CALCIUM; CELLS, CULTURED; CEREBRAL CORTEX; DIOXOLANES; EMBRYO, MAMMALIAN; FIBRINOLYTIC AGENTS; GLUCOSE; GLUTAMIC ACID; HIPPOCAMPUS; HIRUDINS; MICE, INBRED C57BL; NEUROFILAMENT PROTEINS; NEUROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; PROTEIN BINDING; RATS; RECEPTORS, GLUTAMATE; RECOMBINANT PROTEINS; SODIUM; TRITIUM;

EID: 84951569621     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23688     Document Type: Article

References (62)

1. Alkadhi KA, Tian LM. 1996. Veratridine-enhanced persistent sodium current induces bursting in CA1 pyramidal neurons. Neuroscience 71:625-632.
2. Auvin S, Lecointe C, Dupuis N, Desnous B, Lebon S, Gressens P, Dournaud P. 2013. Stiripentol exhibits higher anticonvulsant properties in the immature than in the mature rat brain. Epilepsia 54:2082-2090.
3. 3H]MDL 105, 519, a high-affinity radioligand for the N-methyl-D-aspartate receptor-associated glycine recognition site. J Pharmacol Exp Ther 279:62-68.
4. Bonde C, Noraberg J, Noer H, Zimmer J. 2005. Ionotropic glutamate receptors and glutamate transporters are involved in necrotic neuronal cell death induced by oxygen-glucose deprivation of hippocampal slice cultures. Neuroscience 136:779-794.
5. Bothwell M. 2014. NGF, BDNF, NT3, and NT4. Hdbk Exp Pharmacol 220:3-15.
6. Bradford HF. 1995. Glutamate, GABA, and epilepsy. Prog Neurobiol 47:477-511.
7. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
8. 3H-batrachotoxinin-A benzoate binding to voltage-sensitive sodium channels: inhibition by the channel blockers tetrodotoxin and saxitoxin. J Neurosci 6:2064-2070.
9. Brown-Croyts LM, Caton PW, Radecki DT, McPherson SL. 2000. Phenobarbital pretreatment prevents kainic acid-induced impairments in acquisition learning. Life Sci 67:643-650.
10. Burd I, Bentz AI, Chai J, Gonzalez J, Monnerie H, Le Roux PD, Cohen AS, Yudkoff M, Elovitz MA. 2010. Inflammation-induced preterm birth alters neuronal morphology in the mouse fetal brain. J Neurosci Res 88:1872-1881.
11. Chiron C, Marchand MC, Tran A, Rey E, d'Athis P, Vincent J, Dulac O, Pons G. 2000. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 356:1638-1642.
12. Choi DW. 1992. Excitotoxic cell death. J Neurobiol 23:1261-1276.
13. Choi DW, Koh JY, Peters S. 1988. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J Neurosci 8:185-196.
14. Chung RS, McCormack GH, King AE, West AK, Vickers JC. 2005. Glutamate induces rapid loss of axonal neurofilament proteins from cortical neurons in vitro. Exp Neurol 193:481-488.
15. Coronas V, Arnault P, Roger M. 2002. Cortical diffusible factors increase MAP-2 immunoreactive neuronal population in thalamic cultures. Neurosci Res 43:57-67.
16. Dingledine R, Borges K, Bowie D, Traynelis SF. 1999. The glutamate receptor ion channels. Pharmacol Rev 51:7-61.
17. Doble A. 1999. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 81:163-221.
18. Farwell JR, Anderson GD, Kerr BM, Tor JA, Levy RH. 1993. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia 34:305-311.
19. A receptor as a positive allosteric modulator. Neuropharmacology 56:190-197.
20. Glasgow NG, Siegler RB, Johnson JW. 2015. Molecular bases of NMDA receptor subtype-dependent properties. J Physiol 593:83-95.
21. Glass TF, Reeves B, Sharp FR. 2004. The impact of excitotoxic blockade on the evolution of injury following combined mechanical and hypoxic insults in primary rat neuronal culture. Neurobiol Dis 17:378-384.
22. Greene JG, Greenamyre JT. 1995. Exacerbation of NMDA, AMPA, and L-glutamate excitotoxicity by the succinate dehydrogenase inhibitor malonate. J Neurochem 64:2332-2338.
23. Gupta K, Hardingham GE, Chandran S. 2013. NMDA receptor-dependent glutamate excitotoxicity in human embryonic stem cell-derived neurons. Neurosci Lett 543:95-100.
24. Harrison NL. 1990. On the presynaptic action of baclofen at inhibitory synapses between cultured rat hippocampal neurones. J Physiol 422:433-446.
25. Henshall DC, Meldrum BS. 2012. Cell death and survival mechanisms after single and repeated brief seizures. In: Jasper's basic mechanisms of the epilepsies, 4th ed. New York: Oxford University Press. p 262-276.
26. Inoue Y, Ohtsuka Y. 2014. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence. Epilepsy Res 108:725-731.
27. + ionophore in neuroblastoma cells. Interactions with neurotoxins. J Biol Chem 253:7383-7392.
28. Julien JP, Mushynski WE. 1998. Neurofilaments in health and disease. Prog Nucleic Acid Res Mol Biol 61:1-23.
29. Kaku Y, Yonekawa Y, Tsukahara T, Ogata N, Kimura T, Taniguchi T. 1993. Alterations of a 200 kDa neurofilament in the rat hippocampus after forebrain ischemia. J Cereb Blood Flow Metab 13:402-408.
30. Koh JY, Choi DW. 1991. Selective blockade of non-NMDA receptors does not block rapidly triggered glutamate-induced neuronal death. Brain Res 548:318-321.
31. Lipton P. 1999. Ischemic cell death in brain neurons. Physiol Rev 79:1431-1568.
32. Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W, Stoehr N, Stein T, Gasparini F, Vranesic I, Kuhn R, Nicoletti F, Flor PJ. 2003. (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology 45:895-906.
33. Martin RL, Lloyd HG, Cowan AI. 1994. The early events of oxygen and glucose deprivation: setting the scene for neuronal death? Trends Neurosci 17:251-257.
34. Meldrum BS. 1993. Excitotoxicity and selective neuronal loss in epilepsy. Brain Pathol 3:405-412.
35. Meli E, Picca R, Attucci S, Cozzi A, Peruginelli F, Moroni F, Pellegrini-Giampietro DE. 2002. Activation of mGlu1 but not mGlu5 metabotropic glutamate receptors contributes to postischemic neuronal injury in vitro and in vivo. Pharmacol Biochem Behav 73:439-446.
36. Melo CV, Okumoto S, Gomes JR, Baptista MS, Bahr BA, Frommer WB, Duarte CB. 2013. Spatiotemporal resolution of BDNF neuroprotection against glutamate excitotoxicity in cultured hippocampal neurons. Neuroscience 237:66-86.
37. 3H]kainic acid binding sites in rat CNS as determined by autoradiography. Brain Res 252:91-100.
38. Monaghan DT, Bridges RJ, Cotman CW. 1989. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 29:365-402.
39. Monnerie H, Shashidhara S, le Roux PD. 2003. Effect of excess extracellular glutamate on dendrite growth from cerebral cortical neurons at 3 days in vitro: involvement of NMDA receptors. J Neurosci Res 74:688-700.
40. 3H]alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and a filtration assay. Neurochem Res 12:775-781.
41. Olney JW, Collins RC, Sloviter RS. 1986. Excitotoxic mechanisms of epileptic brain damage. Adv Neurol 44:857-877.
42. Paoletti P, Bellone C, Zhou Q. 2013. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity, and disease. Nat Rev Neurosci 14:383-400.
43. Poisson M, Huguet F, Savattier A, Bakri-Logeais F, Narcisse G. 1984. A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study. Arzneimittelforschung 34:199-204.
44. Quilichini PP, Chiron C, Ben-Ari Y, Gozlan H. 2006. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia 47:704-716.
45. Rekling JC. 2003. Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation. Neurosci Lett 335:167-170.
46. Sanganahalli BG, Joshi PG, Joshi NB. 2006. NMDA and non-NMDA receptors stimulation causes differential oxidative stress in rat cortical slices. Neurochem Int 49:475-480.
47. Saunders DE, DiCerbo JA, Williams JR, Hannigan JH. 1997. Alcohol reduces neurofilament protein levels in primary cultured hippocampal neurons. Alcohol 14:519-526.
48. Shen DD, Levy RH, Moor MJ, Savitch JL. 1990. Efficacy of stiripentol in the intravenous pentylenetetrazol infusion seizure model in the rat. Epilepsy Res 7:40-48.
49. 3H]CGP 39653: a new N-methyl-D-aspartate antagonist radioligand with low nanomolar affinity in rat brain. Eur J Pharmacol 192:19-24.
50. Singer CA, Figueroa-Masot XA, Batchelor RH, Dorsa DM. 1999. The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci 19:2455-2463.
51. Steinschneider R, Delmas P, Nedelec J, Gola M, Bernard D, Boucraut J. 1996. Appearance of neurofilament subunit epitopes correlates with electrophysiological maturation in cortical embryonic neurons cocultured with mature astrocytes. Brain Res Dev Brain Res 95:15-27.
52. Sutula T, Cavazos J, Golarai G. 1992. Alteration of long-lasting structural and functional effects of kainic acid in the hippocampus by brief treatment with phenobarbital. J Neurosci 12:4173-4187.
53. Taylor CP, Weber ML, Gaughan CL, Lehning EJ, LoPachin RM. 1999. Oxygen/glucose deprivation in hippocampal slices: altered intraneuronal elemental composition predicts structural and functional damage. J Neurosci 19:619-629.
54. Trojnar MK, Malek R, Chroscinska M, Nowak S, Blaszczyk B, Czuczwar SJ. 2002. Neuroprotective effects of antiepileptic drugs. Pol J Pharmacol 54:557-566.
55. Van Kanegan MJ, He DN, Dunn DE, Yang P, Newman RA, West AE, Lo DC. 2014. BDNF mediates neuroprotection against oxygen-glucose deprivation by the cardiac glycoside oleandrin. J Neurosci 34:963-968.
56. A receptor potentiation. Br J Pharmacol 171:389-402.
57. 3H]TCP) binds to two different sites in rat brain. Localization by autoradiographic and biochemical techniques. Brain Res 378:133-141.
58. Watkins JC, Krogsgaard-Larsen P, Honore T. 1990. Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol Sci 11:25-33.
59. 3H-stiripentol (author's translation)]. Cell Mol Biol Incl Cyto Enzymol 24:51-60.
60. White HS, Smith MD, Wilcox KS. 2007. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol 81:85-110.
61. Yang J, Wu X, Yu H, Liao X, Teng L. 2014. NMDA receptor-mediated neuroprotective effect of the Scutellaria baicalensis Georgi extract on the excitotoxic neuronal cell death in primary rat cortical cell cultures. Sci World J 2014:459549.
62. Zhou Q, Sheng M. 2013. NMDA receptors in nervous system diseases. Neuropharmacology 74:69-75.